β-Blocker Use and Health Status Among Patients With Heart Failure With Preserved Ejection Fraction

Among patients with heart failure with preserved ejection fraction (HFpEF), is β-blocker use associated with health status or modification of the health status benefits of spironolactone?In this cohort study of 1726 patients with HFpEF from the TOPCAT randomized clinical trial, β-blocker use had no significant association with concurrent health status or modification of the health status benefits of spironolactone at 4 months.These findings suggest that further study is needed to clarify the association of β-blockers with health status among patients with HFpEF, particularly across the range of LVEF.

Corresponding Author: Mohammad Abdel Jawad, MD, Division of Cardiology, Saint Luke’s Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111 (abdeljawadmd@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.